Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Leiomyosarcoma 1Glioblastoma 1

Interventions

Specimen Handling 4Gemcitabine 3Doxorubicin 3liposomal doxorubicin 2Trabectedin 2Magnetic Resonance Spectroscopy 2Dacarbazine 2Biopsy 2toripalimab 1regorafenib 1peposertib 1cemiplimab 1anlotinib 1abemaciclib 1X-Rays 1Tretinoin 1Tissue Banks 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Rosuvastatin Calcium 1Radiotherapy 1Quality of Life 1Nivolumab 1Neoadjuvant Therapy 1Midazolam 1Injections 1Immunoglobulin G 1Ifosfamide 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leiomyosarcoma × ADI PEG20 × Clear all
NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡